Literature DB >> 15741748

Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention.

Harumi Jyonouchi1, Lee Geng, Agnes Ruby, Barbie Zimmerman-Bier.   

Abstract

OBJECTIVE: Our previous study indicated an association between cellular immune reactivity to common dietary proteins (DPs) and excessive proinflammatory cytokine production with endotoxin (lipopolysaccharide, LPS), a major stimulant of innate immunity in the gut mucosa, in a subset of autism spectrum disorder (ASD) children. However, it is unclear whether such abnormal LPS responses are intrinsic in these ASD children or the results of chronic gastrointestinal (GI) inflammation secondary to immune reactivity to DPs. This study further explored possible dysregulated production of proinflammatory and counter-regulatory cytokines with LPS in ASD children and its relationship to GI symptoms and the effects of dietary intervention measures.
METHODS: This study includes ASD children (median age 4.8 years) on the unrestricted (n = 100) or elimination (n = 77) diet appropriate with their immune reactivity. Controls include children with non-allergic food hypersensitivity (NFH; median age 2.9 years) on the unrestricted (n = 14) or elimination (n = 16) diet, and typically developing children (median age 4.5 years, n = 13). The innate immune responses were assessed by measuring production of proinflammatory (TNF-alpha, IL-1beta, IL-6, and IL-12) and counter-regulatory (IL-1ra, IL-10, and sTNFRII) cytokines by peripheral blood mononuclear cells (PBMCs) with LPS. The results were also compared to T-cell responses with common DPs and control T-cell mitogens assessed by measuring T-cell cytokine production.
RESULTS: ASD and NFH PBMCs produced higher levels of TNF-alpha with LPS than controls regardless of dietary interventions. However, only in PBMCs from ASD children with positive gastrointestinal (GI(+)) symptoms, did we find a positive association between TNF-alpha levels produced with LPS and those with cow's milk protein (CMP) and its major components regardless of dietary interventions. In the unrestricted diet group, GI(+) ASD PBMCs produced higher IL-12 than controls and less IL-10 than GI(-) ASD PBMCs with LPS. GI(+) ASD but not GI(-) ASD or NFH PBMCs produced less counter-regulatory cytokines with LPS in the unrestricted diet group than in the elimination diet group. There was no significant difference among the study groups with regard to cytokine production in responses to T-cell mitogens and other recall antigens.
CONCLUSION: Our results revealed that there are findings limited to GI(+) ASD PBMCs in both the unrestricted and elimination diet groups. Thus our findings indicate intrinsic defects of innate immune responses in GI(+) ASD children but not in NFH or GI(-) ASD children, suggesting a possible link between GI and behavioral symptoms mediated by innate immune abnormalities. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741748     DOI: 10.1159/000084164

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  68 in total

Review 1.  Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway.

Authors:  E Carla Parker-Athill; Jun Tan
Journal:  Neurosignals       Date:  2010-10-02

2.  Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13.

Authors:  Zuzana Tobiasova; Klaas H B van der Lingen; Lawrence Scahill; James F Leckman; Yan Zhang; Wookjin Chae; James T McCracken; Christopher J McDougle; Benedetto Vitiello; Elaine Tierney; Michael G Aman; L Eugene Arnold; Liliya Katsovich; Pieter J Hoekstra; Fred Volkmar; Alfred L M Bothwell; Ivana Kawikova
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-11-09       Impact factor: 2.576

Review 3.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

4.  Increased production of IL-17 in children with autism spectrum disorders and co-morbid asthma.

Authors:  Marjannie Eloi Akintunde; Melissa Rose; Paula Krakowiak; Luke Heuer; Paul Ashwood; Robin Hansen; Irva Hertz-Picciotto; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2015-07-11       Impact factor: 3.478

5.  A surprising METamorphosis: autism genetics finds a common functional variant.

Authors:  Matthew W State
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

6.  Maternal exposure to intimate partner abuse before birth is associated with autism spectrum disorder in offspring.

Authors:  Andrea L Roberts; Kristen Lyall; Janet W Rich-Edwards; Alberto Ascherio; Marc G Weisskopf
Journal:  Autism       Date:  2015-02-06

7.  Differential monocyte responses to TLR ligands in children with autism spectrum disorders.

Authors:  Amanda M Enstrom; Charity E Onore; Judy A Van de Water; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2009-08-08       Impact factor: 7.217

Review 8.  Evolution in the Understanding of Autism Spectrum Disorder: Historical Perspective.

Authors:  Mark Mintz
Journal:  Indian J Pediatr       Date:  2016-04-07       Impact factor: 1.967

Review 9.  Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight.

Authors:  Fares Zeidán-Chuliá; José Luiz Rybarczyk-Filho; Alla B Salmina; Ben-Hur Neves de Oliveira; Mami Noda; José Cláudio F Moreira
Journal:  Neuromolecular Med       Date:  2013-03-02       Impact factor: 3.843

10.  Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial.

Authors:  Daniel A Rossignol; Lanier W Rossignol; Scott Smith; Cindy Schneider; Sally Logerquist; Anju Usman; Jim Neubrander; Eric M Madren; Gregg Hintz; Barry Grushkin; Elizabeth A Mumper
Journal:  BMC Pediatr       Date:  2009-03-13       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.